Supporting data for “The Role of STING on Immune Response and Overcoming Resistance to anti-PD-1 Therapy in Hepatocellular Carcinoma"

Recently, the FDA approved two anti-PD-1 inhibitors as the second line therapies for patients with advanced hepatocellular carcinoma (HCC). However, a significant number of HCC patients do not respond to PD-1 blockade therapy, underlying the need of urgent to understand the mechanisms behind this lack of response. This understanding is essential for effective patient stratification and the development of tailored immunotherapy strategies. Additionally, β-catenin (encoded by CTNNB1) mutations occur in around 11-37% of hepatocellular carcinoma (HCC) patients. A hallmark of β-catenin-mutant solid tumors is T cell exclusion, besides, others reported that β-catenin mutation drives resistance to anti-PD-1 immunotherapy in cancers, in this study, we uncovered a cell-autonomous mechanism of immune evasion and raised a novel therapeutic strategy to enhance anti-PD-1 efficacy in HCCs.